Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Major depressive disorder (MDD), also referred to as depression, is a severe medical illness that disrupts a person’s mood, behavior, thought processes, and physical health. Sadness and grief are normal reactions to life stresses. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme “high” feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The decline in hippocampal function, which is believed to have an inhibitory effect on the hypothalamic-pituitary-adrenal (HPA) axis, could potentially be responsible for the hypercortisolemia seen in depression. Pro-inflammatory marker levels are reported to be elevated in depressed patients, such as C-reactive protein (CRP), interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α).

·       According to research, the prevalence of major depressive disorder (MDD) differs significantly across geographies, including the US (7.1%, 16.2 M) and Japan (4.7%, 5.0 M). In the US, MDD sufferers were more likely to be women than non-sufferers and were significantly younger (ps<0.05).

Thelansis’s “Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder (MDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Major Depressive Disorder (MDD) across the 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Major Depressive Disorder (MDD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033